L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
AssigneeThe Institute for Ethnomedicine
InventorsPaul Alan Cox, Sandra Anne Banack, Deborah C. Mash
Life of this patent
Estimating the term…
Abstract
L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and/or prevention of protein aggregation/tangles/plaques and diseases associated with protein aggregation/tangles/plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).
Claims10
A non-human primate model of a neurodegnerative disease, wherein the model is produced by administration of BMAA to the non-human primate.
A method for identifying an agent for prophylactic treatment of a neurodegnerative disease comprising:
- a) contacting a non-human primate prior to administration of BMAA with a candidate agent;
- b) administering BMAA to the non-human primate;
- and
- c) determining if the candidate agent inhibits or reduces neuroprotein misfolding or neuroprotein aggregates in the non-human primate administered, wherein an inhibition or reduction neuroprotein misfolding or neuroprotein aggregates identifies the candidate agent as an agent for prophylactic treatment of a neurodegnerative disease.
Dependencies are inferred from the claim text.